Chondroitin Sulfate Global Market Report 2024

The chondroitin sulfate market size has grown steadily in recent years. It will grow from $1.38 billion in 2023 to $1.44 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historical period regarding chondroitin sulfate can be attributed to several factors. These include the expanding aging population and increased awareness about joint health, the prevalence of osteoarthritis and various joint disorders prompting interest in solutions such as chondroitin sulfate, the growth and expansion of the dietary supplement industry, heightened consumer interest in natural and nutraceutical products, and an increase in participation in sports and fitness activities, where joint health is a significant concern.

The chondroitin sulfate market size is expected to see strong growth in the next few years. It will grow to $1.76 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. Anticipated growth in the forthcoming period regarding chondroitin sulfate can be attributed to several factors. These include the widening applications of chondroitin sulfate in veterinary medicine, ongoing research advancements and validated clinical studies further supporting its efficacy, a global increase in lifestyle-related joint issues fostering its use, incorporation into functional foods and beverages for enhanced joint health, and strategic marketing initiatives and health campaigns promoting its benefits. Key trends expected in the forecast period encompass a focus on sustainable sourcing practices for chondroitin sulfate, advancements in extraction and production technologies to improve its efficiency and quality, a growing market for pet nutraceuticals utilizing chondroitin sulfate, increased awareness campaigns highlighting the benefits of joint health, and an expanded global market presence for chondroitin sulfate-based products.

The chondroitin sulfate market is anticipated to experience growth driven by the increasing incidences of osteoarthritis. Osteoarthritis, a prevalent form of arthritis affecting millions globally, results from the gradual deterioration of the protective cartilage that cushions bone ends. Chondroitin sulfate proves effective in treating osteoarthritis by offering resistance to compression, maintaining structural integrity, promoting homeostasis, slowing down the degenerative process, and alleviating muscular pain. The escalating incidences of osteoarthritis are expected to drive the demand for chondroitin sulfate. For instance, In May 2022 As per statistics published by Amgen, a US-based biotechnology company, osteoporosis causes approximately 1.5 million fractures annually in the United States, leading to $19 billion in associated costs. Furthermore, it is projected that the annual number of fractures caused by osteoporosis will increase by 68% by 2040, reaching 3.2 million. The growing prevalence of osteoarthritis is thus poised to fuel the growth of the chondroitin sulfate market.

The chondroitin sulfate market is set to benefit from the increasing demand in the pharmaceutical industry. The pharmaceutical industry, dedicated to research, development, production, and marketing of drugs and medications for medical treatment, utilizes chondroitin sulfate in joint health supplements. These supplements provide relief from pain and swelling associated with various joint disorders and are employed in transdermal drug delivery systems. In June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that the total pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from the previous year. This upward trend in pharmaceutical demand is a significant driver for the growth of the chondroitin sulfate market.

The growth of the chondroitin sulfate market is further propelled by the rising demand for nutraceutical products. Nutraceuticals, characterized as substances offering physiological benefits or protection against chronic ailments, aim to enhance overall health, prevent chronic conditions, increase longevity, or support the structure and function of the body. Chondroitin sulfate, a popular dietary ingredient, is used in nutraceuticals to alleviate symptoms associated with osteoarthritis. In December 2022, the Office of Dietary Supplements (ODS), a US-based department within the National Institutes of Health (NIH), reported total sales of dietary supplements in the United States amounting to $60 billion in 2021. The growing demand for nutraceutical products is thus contributing to the expansion of the chondroitin sulfate market.

Product innovation stands out as a prominent trend gaining traction in the chondroitin sulfate market. Major companies within the market are actively introducing new products to fortify their positions and meet evolving consumer needs. A noteworthy example is the launch by Infinitus, a China-based herbal health products and services company, in July 2022. Infinitus introduced a new series of Li Mai Jian supplements with a theme centered around 'Making Bones Stronger for Joint Health.' Scientifically formulated with coix seeds and lobed kudzu vine root, these supplements provide additional care for joints, reflecting the industry's commitment to advancing product offerings.

Strategic partnerships have become a focal point for major companies in the chondroitin sulfate market, enabling them to enhance profitability and achieve mutual benefits. One such instance occurred in March 2022, when Bioiberica Nebraska Inc., a US-based life science company specializing in chondroitin sulfate, entered into a partnership with ByHealth. This collaboration aims to develop a new product for Bioiberica Nebraska Inc.'s joint health brand, Highflex, tailored for the Chinese market. The partnership also involves educating Chinese consumers about the benefits of collagen supplementation on joint health. ByHealth, a China-based company, is a provider of vitamins and dietary supplements (VDS). Additionally, in April 2021, Bioiberica Nebraska Inc. partnered with Apsen Pharmaceuticals. Through this collaboration, Bioiberica Nebraska Inc. seeks to develop the mobility product Motilex HA in Brazil, combining b-2Cool native type II collagen with chondroitin sulfate, glucosamine hydrochloride, and Mobilee, a patented ingredient. Apsen Pharmaceuticals, based in Brazil, is a pharmaceutical company that provides chondroitin sulfate. These strategic partnerships underscore the industry's commitment to expanding market reach and bringing innovative solutions to consumers worldwide.

Major companies operating in the chondroitin sulfate market report are Seikagaku Corporation, Synutra Ingredients, Yantai Ruikangda Biochemical Products Co.ltd., TSI Group Ltd., Sioux Pharm, Summit Nutritionals International Inc., ZPD A/S, Sino Siam Bio technique Co. Ltd., Bio-gen Extracts Pvt. Ltd., Hebei Sanxin industry Group Co.Ltd., Sigma Aldrich Inc., Fidia Farmaceutici S.p.A., Shandong Runxin Biotechnology Co. Ltd., Gnosis S.p.A., Pacific Rainbow International Inc., Bioiberica S.A.U., Merck KGaA, Ruikangda Biochemical Co. Ltd., Guanglong Biochem Co. Ltd., Nippon Zoki Pharmaceutical Co. Ltd., Huiwen Technology Co. Ltd., Runxin Biotechnology Co. Ltd., Yangtze River Basin Construction Co. Ltd., Focus Technology Co. Ltd., SANXIN, WanTuMing Biological, QJBCHINA, Hengjie Bio-Pharmaceuticals, Rochem International Inc., Chongqing Aoli Biopharmaceutical Co. Ltd..

North America was the largest region in the chondroitin sulfate market in 2023. Asia-Pacific is expected to be the fastest-growing region in the chondroitin sulfate market report during the forecast period. The regions covered in the chondroitin sulfate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chondroitin sulfate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary forms of chondroitin sulfate include capsules, tablets, and powder formulations. Capsules are measured-out containers containing medication that dissolves upon ingestion. Chondroitin sulfate is sourced from various origins, including bovine, swine, poultry, shark, and synthetic sources. It finds applications in pet food and veterinary supplements, pharmaceutical and biotech industries, cosmetics, and personal care products.

The chondroitin sulfate market research report is one of a series of new reports that provides chondroitin sulfate market statistics, including chondroitin sulfate industry global market size, regional shares, competitors with a chondroitin sulfate market share, detailed chondroitin sulfate market segments, market trends and opportunities, and any further data you may need to thrive in the chondroitin sulfate industry. This chondroitin sulfate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.